Funding Opportunities for Entrepreneurs

Dr Shilpa Deshpande Kaistha
Department of Biotechnology
School of Life Sciences & Biotechnology
CSJM University Kanpur

Government Grants and Research Funding in India

- **(i) BIRAC (Biotechnology Industry Research Assistance Council) Grants**
- BIRAC, under the **Department of Biotechnology (DBT), Government of India**, provides several funding schemes for biotech and microbial startups:
- **Biotechnology Ignition Grant (BIG)**
  - Provides **₹50 lakh (~$60,000) for early-stage biotech startups**.
  - Supports **proof-of-concept and prototype development**.
  - Open to **individual entrepreneurs, academia, and early-stage startups**.
  - Example: Startups developing **microbial probiotics, phage therapy, or biofertilizers**.
- **Small Business Innovation Research Initiative (SBIRI)**
  - Provides funding for **R&D in biotech startups** working on high-risk innovations.
  - Grants **up to ₹1 crore (~$120,000)** for prototype development.
  - Supports translational research in **microbial drug development, biofuels, and sustainable agriculture**.
- **Biotechnology Industry Partnership Programme (BIPP)**
  - Supports **public-private partnerships in applied biotech research**.
  - Provides **50-90% grant-in-aid** for startups working on **microbial therapeutics, diagnostics, and biomanufacturing**.
- **PACE (Promoting Academic Research and Converting Innovations into Enterprises)**
  - Focuses on **academic startups** that want to commercialize microbial research.
  - Encourages **technology transfer from universities to industry**.

- **(ii) Startup India Seed Fund Scheme (SISFS)**
  - Provides **up to ₹50 lakh (~$60,000)** to early-stage startups.
  - Covers **product development, regulatory approvals, market-entry, and commercialization**.
  - Ideal for **microbial biotech startups working on fermentation-based products, probiotics, and bio-based materials**.
- **(iii) NIDHI (National Initiative for Developing and Harnessing Innovations)**
  - NIDHI, under **DST (Department of Science & Technology)**, funds deep-tech microbial startups:
  - **NIDHI PRAYAS** – Offers **₹10 lakh (~$12,000)** for prototype development.
  - **NIDHI EIR (Entrepreneur-in-Residence)** – Supports **individual entrepreneurs with ₹30,000-₹50,000 per month**.
  - **NIDHI Accelerator** – Helps startups with **market validation and funding connections**.
- **(iv) Atal Innovation Mission (AIM) Grants**
  - Provides funding through **Atal Incubation Centres (AICs)** for biotech startups.
  - Supports innovations in **agriculture, healthcare, environment, and industrial microbiology**.
  - Ideal for startups in **microbial drug discovery, synthetic biology, and enzyme production**.
- **(v) National Biopharma Mission (NBM)**
  - A **DBT initiative** supporting microbial and biopharmaceutical startups.
  - Provides **grants and soft loans for R&D, clinical trials, and manufacturing**.
  - Focuses on **vaccines, biosimilars, microbial therapeutics, and precision medicine**.

Types of Funding

- **Bootstrapping:** Bootstrapping involves using personal savings, revenue from the business, or support from friends and family to fund a startup. Very generally speaking, this is usually how companies get their initial start. Pre Seed Funding
- **Crowdfunding:** Crowdfunding raises small amounts of money from a large number of people through platforms like Kickstarter, Indiegogo, or GoFundMe. This method can validate the product idea and build a customer base without equity dilution since crowdfunded capital is not tied to share or equity offerings.
- **Revenue-Based Financing:** Revenue-based financing involves selling a percentage of future revenue to investors for immediate funds. This option avoids equity dilution and offers flexible repayment tied to revenue. However, it can be expensive if the company grows rapidly, and some companies won't even have this as an option if it has unpredictable revenue streams.
- **Bank Loans and Lines of Credit:** If equity isn't preferred, traditional debt financing through bank loans or lines of credit provides capital without equity dilution. Note that debt may have a higher cost of capital than equity offerings.
- **Angel Investors:** Seed funding is the first official equity funding stage. It typically represents the first official money a business venture or enterprise raises**.** Seed funding helps a company finance its first steps, including market research and product development. With seed funding, a company has assistance in determining what its final products will be and who its target demographic is. Seed funding is generally used to employ a founding team to complete these tasks.
- **Corporate Venture Capital:** Corporate venture capital involves large corporations investing in startups for strategic reasons rather than purely financial returns. Though this largely mimics what a series funding may look like, the dynamics may be different as the corporation may look to provide more expertise or resources compared to more traditional private equity offerings.

Angel Investors in India for Biotech Startups

- **Angel investors** are high-net-worth individuals or groups who provide early-stage funding to startups in exchange for equity.
- For biotech entrepreneurs, angel investors can be crucial for **prototyping, regulatory approvals, and initial market entry**. India has several active angel investment groups focusing on biotechnology, healthcare, and microbial startups.
- Angel investors help biotech startups by providing:
  - ☑ **Seed funding** for early-stage research and development.
  - ☑ **Mentorship and industry connections** to scale the business.
  - ☑ **Regulatory and compliance guidance** for biotech products.
  - ☑ **Business strategy support** for commercialization.

Leading Angel Investor Groups in India Supporting Biotech Startups

- **(i) Indian Angel Network (IAN)**
  - **India's largest angel investment network** with over **500 investors**.
  - Invests in **biotech, healthcare, agri-tech, and deep-tech startups**.
  - Average investment: **₹50 lakh to ₹10 crore (~$60,000 to $1.2 million)**.
  - Notable biotech investment: **Consure Medical (medical devices), Uniphore (speech AI for healthcare)**.
  - Website: www.indianangelnetwork.com
- **(ii) Mumbai Angels Network**
  - Focuses on **early-stage biotech, pharma, and life sciences startups**.
  - Investment range: **₹1 crore to ₹5 crore (~$120,000 to $600,000)**.
  - Funded biotech startups like **Innaumation Medical Devices, String Bio (synthetic biology), and Axio Biosolutions (wound care biotech)**.
  - Website: www.mumbaiangels.com

- **(iii) Lead Angels**
  - Invests in **biotech startups working on diagnostics, therapeutics, and industrial microbiology**.
  - Average funding: **₹50 lakh to ₹3 crore (~$60,000 to $360,000)**.
  - Notable investment: **Bugworks Research (antibiotic resistance solutions)**.
  - Website: www.leadangels.in
- **(iv) Hyderabad Angels**
  - Supports biotech startups in **healthcare, agritech, and biopharmaceuticals**.
  - Investment range: **₹1 crore to ₹10 crore (~$120,000 to $1.2 million)**.
  - Notable biotech investment: **Biodesign Innovation Labs (medical biotech)**.
  - Website: www.hyderabadangels.in

- **(v) Chennai Angels**
  - Focuses on **biotech startups working on sustainable agriculture, fermentation-based products, and diagnostics**.
  - Invests **₹50 lakh to ₹5 crore (~$60,000 to $600,000)**.
  - Notable biotech startup funded: **Yostra Labs (medical devices for neurological disorders)**.
  - Website: www.thechennaiangels.com

- **Case Study: Bugworks Research**
  - **Sector**: Antimicrobial resistance solutions.
  - **Angel Network Support**: Received **funding from Lead Angels and IAN**.
  - **Investment Raised**: **₹100 crore (~$12 million)** from a mix of angel investors and VC firms.
  - **Impact**: Developing **new-generation antibiotics** against drug-resistant bacteria.

(vi) Villgro Innovations Foundation *(Impact-Driven Angel Network)*

- Specializes in social impact biotech and agritech startups.
- Supports biotech-based sustainable agriculture, food security, and healthcare solutions.
- Provides funding, incubation, and mentorship.
- Notable investment: Sea6 Energy (marine biotechnology for biofuels and sustaina

(vii) LetsVenture *(Angel Network + Crowdfunding for Biotech)*ble agriculture).Website: www.villgro.org

- Connects biotech startups with angel investors via **online funding platform**.
- Helps in **early-stage funding and Series A investments**.

The initial investment—also known as seed funding—is followed by various rounds, known as Series A, B, and C.

Venture Capitalists (VC Firms)

- **Venture capital** is a form of private equity financing provided by firms or funds to startup, early-stage, and emerging companies, that have been deemed to have high growth potential or that have demonstrated high growth in terms of number of employees, annual revenue, scale of operations, etc
- **A venture capitalist**, or sometimes simply called a capitalist, is a person who makes capital investments in companies in exchange for an equity stake
- The Shark Tank are venture capitalists, meaning that they provide capital (money) to companies with the potential for growth in exchange for equity stake

Venture Capital firms

- **What Is Series A Funding?**
  - The first round after the seed stage is Series A funding. The term gets its name from the preferred stock sold to investors at this stage. In this round, it's important to have a plan for developing a business model that will generate long-term profit.
  - investors are not just looking for great ideas. Rather, they are looking for companies with great ideas and a strong strategy for turning that idea into a successful, money-making business.
  - Well-known venture capital firms that participate in Series A funding include Sequoia Capital, IDG Capital, Google Ventures, and Intel Capital.
- **Limitations of Series A Funding**
  - **Dilution of Ownership**: Founders often give up a significant portion of their ownership in exchange for capital. This dilution can reduce their control over the company, and this is the first time the initial owners of the company may experience this.
  - **Increased Expectations**: Investors in Series A rounds typically expect rapid growth and significant progress. This can put pressure on the startup to meet aggressive targets.
  - **Loss of Autonomy**: Investors may demand a say in business decisions, adding external influence on the company's direction and strategy. Whereas a company was more largely autonomous before, it now may have to take some direction from external parties.
  - **Early Financial Burden**: Although it's an infusion of capital, there might be an increased financial burden to meet investor expectations and demonstrate growth. This is especially true for Series A where risk is often highest (meaning investors expect rewards to also be highest).

- **What Is Series B Funding?**
  - Series B rounds are about taking businesses to the next level, past the development stage. Investors help startups get there by expanding market reach.
  - Companies that have gone through seed and Series A funding rounds have already developed substantial user bases and have proven to investors that they are prepared for success on a larger scale.
  - Series B funding is used to grow the company so that it can meet these levels of demand.

- **Limitations of Series B Funding**
  - Further Dilution: As with Series A, Series B funding usually involves giving up more equity, further diluting the founders' stakes. This also poses potential threats to existing owners from prior rounds.
  - Pressure to Scale: Also as with Series A, Series B investors expect the company to scale significantly. This can lead to pressure on the company to expand rapidly. Note that some investors at this point may be tepid at the fact that the company may be asking for more capital without having made substantial progress as hoped or expected.
  - Higher Stakeholder Expectations: The involvement of more sophisticated investors means higher expectations for governance, reporting, and performance metrics. This is more true in Series B funding where multiple rounds of capital have been achieved and operational expectations have been set.

- **How Series C Funding Works?**
  - In Series C, groups such as hedge funds, investment banks, private equity firms, and large secondary market groups accompany the type of investors mentioned above.
  - The reason for this is that the company has already proven itself to have a successful business model; these new investors come to the table expecting to invest significant sums of money into companies that are already thriving as a means of helping to secure their own position as business leaders.
  - Most commonly, a company will end its external equity funding with Series C.
  - For the most part, companies gaining up to hundreds of millions of dollars in funding through Series C rounds are prepared to continue developing globally.
- **Limitations of Series C Funding**
  - **Significant Dilution**: By the time a company reaches Series C, founders might have given up a substantial amount of ownership, significantly diluting their control.
  - **Intense Growth Pressure**: Series C funding is often used for scaling operations on a global level, which brings even more immense pressure to achieve high growth rates.
  - **Exit Strategy Focus**: Investors at this stage are often looking for a clear path to exit, such as an IPO or acquisition. This can push the company towards decisions that favor short-term gains over long-term sustainability.
  - **Cultural Shifts**: As the company grows, maintaining the original startup culture becomes challenging. This is especially true if the company is now targeting an IPO and must manage public stock price expectations.



https://blog.privateequitylist.com/india-private-equity-and-venture-capital-pe-vc-market-map/

Initial Public Offering

- The full form of IPO is **Initial Public Offering.**
- An IPO is the process where a private company offers its shares to the public for the first time.
- This helps the company raise equity capital from individuals and institutional investors, transforming it from a privately owned entity into a publicly traded one.
- Eligibility Criteria for IPO Filing

  A minimum operating history of 3 years (varies by jurisdiction). Positive net tangible assets in the past 2-3 financial years. Minimum paid-up capital and net worth requirements. Compliance with financial reporting and governance norms
- **Biocon Ltd-**biopharmaceuticals, generic formulations, and biosimilars
- Concord Biotech Ltd specializes in fermentation-based APIs, serving global markets with high-quality biopharmaceuticals.
- **Sun Pharma Advanced Research Company Ltd** (SPARC) is a research-driven entity focusing on novel drug delivery systems and innovative formulations in oncology. It leverages cutting-edge technology to address unmet medical needs, strengthening its position in the global pharmaceutical R&D space.

References

- https://www.investopedia.com/articles/personal-finance/102015/series-b-c-funding-what-it-all-means-and-how-it-works.asp